We found noevidence of differences in sex (P = .018), age(P = .817), smoking status (P = .209),lymph node involvement (P = .357), early-stage adenocarcinoma(P = .153), lepidic growth adenocarcinoma(P = .018), or EGFR mutation(P = .652) between the two groups (Table 3). This evidence concerns the gene EGFR and adenocarcinoma.